Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee

被引:14
|
作者
Nicely, Nathan I. [1 ]
Wiehe, Kevin [1 ]
Kepler, Thomas B. [2 ]
Jaeger, Frederick H. [1 ]
Dennison, S. Moses [1 ]
Rerks-Ngarm, Supachai [3 ]
Nitayaphan, Sorachai [4 ]
Pitisuttithum, Punnee [5 ]
Kaewkungwal, Jaranit [5 ]
Robb, Merlin L. [6 ]
O'Connell, Robert J. [4 ]
Michael, Nelson L. [7 ]
Kim, Jerome H. [7 ]
Liao, Hua-Xin [1 ]
Alam, S. Munir [1 ]
Hwang, Kwan-Ki [1 ]
Bonsignori, Mattia [1 ]
Haynes, Barton F. [1 ]
机构
[1] Duke Univ, Sch Med, Duke Human Vaccine Inst, Durham, NC 27708 USA
[2] Boston Univ, Dept Microbiol, Boston, MA 02215 USA
[3] Minist Publ Hlth, Nonthaburi, Thailand
[4] Armed Forces Res Inst Med Sci, Bangkok, Thailand
[5] Mahidol Univ, Bangkok 10700, Thailand
[6] US Mil HIV Res Program, Henry Jackson Fdn HIV Program, Bethesda, MD USA
[7] Walter Reed Army Inst Res, US Mil HIV Res Program MHRP, Silver Spring, MD USA
来源
EBIOMEDICINE | 2015年 / 2卷 / 07期
关键词
HIV-1; Gp120; V2; RV-144; Antibody maturation; Germline; Unmutated ancestor; NEUTRALIZING ANTIBODIES; AFFINITY MATURATION; INTEGRIN ALPHA(4)BETA(7); CRYSTAL-STRUCTURE; IMMUNE-RESPONSE; BROAD; RECOGNITION; EVOLUTION; BINDING; FLEXIBILITY;
D O I
10.1016/j.ebiom.2015.06.016
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Human monoclonal antibody CH58 isolated from an RV144 vaccinee binds at Lys169 of the HIV-1 Env gp120 V2 region, a site of vaccine-induced immune pressure. CH58 neutralizes HIV-1 CRF_ 01 AE strain 92TH023 and mediates ADCC against CD4+T cell targets infected with CRF_ 01 AE tier 2 virus. CH58 and other antibodies that bind to a gp120 V2 epitope have a second light chain complementarity determining region (LCDR2) bearing a glutamic acid, aspartic acid (ED) motif involved in forming salt bridges with polar, basic side amino acid side chains in V2. In an effort to learn how V2 responses develop, we determined the crystal structures of the CH58-UA antibody unliganded and bound to V2 peptide. The structures showed an LCDR2 structurally preconformed from germline to interact with V2 residue Lys169. LCDR3 was subject to conformational selection through the affinity maturation process. Kinetic analyses demonstrate that only a few contacts were responsible for a 2000-fold increase in KD through maturation, and this effect was predominantly due to an improvement in off-rate. This study shows that preconformation and preconfiguration can work in concert to produce antibodies with desired immunogenic properties. (C) 2015 The Authors. Published by Elsevier B. V.
引用
收藏
页码:713 / 722
页数:10
相关论文
共 13 条
  • [1] Structural Analysis of the Unmutated Common Ancestor Antibodies of the HIV Envelope V2 Antibodies CH58 and CH59 Derived from RV144 Vaccinees
    Nicely, N. I.
    Wiehe, K.
    Kepler, T. B.
    Jaeger, F. H.
    Dennison, S. M.
    Liao, H.
    Alam, S. M.
    Rerks-Ngarm, S.
    Nitayaphan, S.
    Pitisuttithum, P.
    Kaewkungwal, J.
    Michael, N. L.
    Kim, J. H.
    Haynes, B. F.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2013, 29 (11) : A167 - A168
  • [2] Analysis of HLA A☆02 Association with Vaccine Efficacy in the RV144 HIV-1 Vaccine Trial
    Gartland, Andrew J.
    Li, Sue
    McNevin, John
    Tomaras, Georgia D.
    Gottardo, Raphael
    Janes, Holly
    Fong, Youyi
    Morris, Daryl
    Geraghty, Daniel E.
    Kijak, Gustavo H.
    Edlefsen, Paul T.
    Frahm, Nicole
    Larsen, Brendan B.
    Tovanabutra, Sodsai
    Sanders-Buell, Eric
    deCamp, Allan C.
    Magaret, Craig A.
    Ahmed, Hasan
    Goodridge, Jodie P.
    Chen, Lennie
    Konopa, Philip
    Nariya, Snehal
    Stoddard, Julia N.
    Wong, Kim
    Zhao, Hong
    Deng, Wenjie
    Maust, Brandon S.
    Bose, Meera
    Howell, Shana
    Bates, Adam
    Lazzaro, Michelle
    O'Sullivan, Annemarie
    Lei, Esther
    Bradfield, Andrea
    Ibitamuno, Grace
    Assawadarachai, Vatcharain
    O'Connell, Robert J.
    Desouza, Mark S.
    Nitayaphan, Sorachai
    Rerks-Ngarm, Supachai
    Robb, Merlin L.
    Sidney, John
    Sette, Alessandro
    Zolla-Pazner, Susan
    Montefiorl, David
    McElrath, M. Juliana
    Mullins, James I.
    Kim, Jerome H.
    Gilbert, Peter B.
    Hertz, Tomer
    JOURNAL OF VIROLOGY, 2014, 88 (15) : 8242 - 8255
  • [3] Comprehensive Sieve Analysis of Breakthrough HIV-1 Sequences in the RV144 Vaccine Efficacy Trial
    Edlefsen, Paul T.
    Rolland, Morgane
    Hertz, Tomer
    Tovanabutra, Sodsai
    Gartland, Andrew J.
    decamp, Allan C.
    Magaret, Craig A.
    Ahmed, Hasan
    Gottardo, Raphael
    Juraska, Michal
    McCoy, Connor
    Larsen, Brendan B.
    Sanders-Buell, Eric
    Carrico, Chris
    Menis, Sergey
    Bose, Meera
    Arroyo, Miguel A.
    O'Connell, Robert J.
    Nitayaphan, Sorachai
    Pitisuttithum, Punnee
    Kaewkungwal, Jaranit
    Rerks-Ngarm, Supachai
    Robb, Merlin L.
    Kirys, Tatsiana
    Georgiev, Ivelin S.
    Kwong, Peter D.
    Scheffler, Konrad
    Pond, Sergei L. Kosakovsky
    Carlson, Jonathan M.
    Michael, Nelson L.
    Schief, William R.
    Mullins, James I.
    Kim, Jerome H.
    Gilbert, Peter B.
    PLOS COMPUTATIONAL BIOLOGY, 2015, 11 (02)
  • [4] Comprehensive Sieve Analysis of Breakthrough HIV-1 Sequences in the RV144 Vaccine Efficacy Trial
    Edlefsen, Paul T.
    Rolland, Morgane
    Hertz, Tomer
    Tovanabutra, Sodsai
    Gartland, Andrew J.
    deCamp, Allan C.
    Magaret, Craig A.
    Ahmed, Hasan
    Gottardo, Raphael
    Juraska, Michal
    McCoy, Connor
    Larsen, Brendan B.
    Sanders-Buell, Eric
    Carrico, Chris
    Menis, Sergey
    Bose, Meera
    Arroyo, Miguel A.
    O'Connell, Robert J.
    deSouza, Mark S.
    Nitayaphan, Sorachai
    Pitisuttithum, Punnee
    Kaewkungwal, Jaranit
    Rerks-Ngarm, Supachai
    Robb, Merlin L.
    McLellan, Jason S.
    Georgiev, Ivelin S.
    Kirys, Tatsiana
    Kwong, Peter D.
    Carlson, Jonathan M.
    Michael, Nelson L.
    Schief, William R.
    Mullins, James I.
    Kim, Jerome H.
    Gilbert, Peter B.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2014, 30 : A25 - A26
  • [5] The Thai Phase III Trial (RV144) Vaccine Regimen Induces T Cell Responses That Preferentially Target Epitopes within the V2 Region of HIV-1 Envelope
    de Souza, Mark S.
    Ratto-Kim, Silvia
    Chuenarom, Weerawan
    Schuetz, Alexandra
    Chantakulkij, Somsak
    Nuntapinit, Bessara
    Valencia-Micolta, Anais
    Thelian, Doris
    Nitayaphan, Sorachai
    Pitisuttithum, Punnee
    Paris, Robert M.
    Kaewkungwal, Jaranit
    Michael, Nelson L.
    Rerks-Ngarm, Supachai
    Mathieson, Bonnie
    Marovich, Mary
    Currier, Jeffrey R.
    Kim, Jerome H.
    JOURNAL OF IMMUNOLOGY, 2012, 188 (10): : 5166 - 5176
  • [6] Role of Vaccine-induced V2 Antibodies in Protection from HIV Infection of Recipients in the RV144 Clinical Vaccine Trial
    Zolla-Pazner, Susan
    Williams, Constance
    deCamp, Allan
    Morris, Daryl
    Haynes, Barton
    Kim, Jerome
    Michael, Nelson
    Rao, Mangala
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2012, 59 : 46 - 46
  • [7] Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial
    Gottardo, Raphael
    Bailer, Robert T.
    Korber, Bette T.
    Gnanakaran, S.
    Phillips, Joshua
    Shen, Xiaoying
    Tomaras, Georgia D.
    Turk, Ellen
    Imholte, Gregory
    Eckler, Larry
    Wenschuh, Holger
    Zerweck, Johannes
    Greene, Kelli
    Gao, Hongmei
    Berman, Phillip W.
    Francis, Donald
    Sinangil, Faruk
    Lee, Carter
    Nitayaphan, Sorachai
    Rerks-Ngarm, Supachai
    Kaewkungwal, Jaranit
    Pitisuttithum, Punnee
    Tartaglia, James
    Robb, Merlin L.
    Michael, Nelson L.
    Kim, Jerome H.
    Zolla-Pazner, Susan
    Haynes, Barton F.
    Mascola, John R.
    Self, Steve
    Gilbert, Peter
    Montefiori, David C.
    PLOS ONE, 2013, 8 (09):
  • [8] HLA class II diversity in HIV-1 uninfected individuals from the placebo arm of the RV144 Thai vaccine efficacy trial
    Baldwin, K. M.
    Ehrenberg, P. K.
    Geretz, A.
    Prentice, H. A.
    Nitayaphan, S.
    Rerks-Ngarm, S.
    Kaewkungwal, J.
    Pitisuttithum, P.
    O'Connell, R. J.
    Kim, J. H.
    Thomas, R.
    TISSUE ANTIGENS, 2015, 85 (02): : 117 - 126
  • [9] HLA Class II Genes Interact with the Immune Correlates from the RV144 Vaccine Efficacy Trial and Impact HIV-1 Acquisition
    Prentice, H.
    Geraghty, D. E.
    Tomaras, G. D.
    Fong, Y.
    Nelson, W.
    Kijak, G. H.
    Zolla-Pazner, S.
    Nitayaphan, S.
    Rerks-Ngarm, S.
    Kaewkungwal, J.
    Pitisuttithum, P.
    Gilbert, P. B.
    Haynes, B. F.
    Kim, J. H.
    Michael, N.
    Thomas, R.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2013, 29 (11) : A178 - A178
  • [10] Analysis of V2 Antibody Responses Induced in Vaccinees in the ALVAC/AIDSVAX HIV-1 Vaccine Efficacy Trial
    Zolla-Pazner, Susan
    deCamp, Allan C.
    Cardozo, Timothy
    Karasavvas, Nicos
    Gottardo, Raphael
    Williams, Constance
    Morris, Daryl E.
    Tomaras, Georgia
    Rao, Mangala
    Billings, Erik
    Berman, Phillip
    Shen, Xiaoying
    Andrews, Charla
    O'Connell, Robert J.
    Ngauy, Viseth
    Nitayaphan, Sorachai
    de Souza, Mark
    Korber, Bette
    Koup, Richard
    Bailer, Robert T.
    Mascola, John R.
    Pinter, Abraham
    Montefiori, David
    Haynes, Barton F.
    Robb, Merlin L.
    Rerks-Ngarm, Supachai
    Michael, Nelson L.
    Gilbert, Peter B.
    Kim, Jerome H.
    PLOS ONE, 2013, 8 (01):